Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YEHUDA HANDELSMAN

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1063453769
CMS profile
275464
Location
TARZANA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$121,681.21

150 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YEHUDA HANDELSMAN

NPI 1063453769 · CMS profile ID 275464

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

TARZANA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063453769?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YEHUDA HANDELSMAN, NPI 1063453769, CMS profile ID 275464. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063453769?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). YEHUDA HANDELSMAN, NPI 1063453769, CMS profile ID 275464. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063453769?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
YEHUDA HANDELSMAN, NPI 1063453769, CMS profile ID 275464, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1063453769?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

150 matching records · $121,681.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 150 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 150.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $250.1704/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898755101 CMS
Novo Nordisk Inc $666.4004/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898996756 CMS
Novo Nordisk Inc $262.0104/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899235971 CMS
Novo Nordisk Inc $6,436.5004/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899480207 CMS
Esperion Therapeutics, Inc. $520.0004/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258443 CMS
Novo Nordisk Inc $1,224.1104/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898719149 CMS
Novo Nordisk Inc $347.9604/05/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899331393 CMS
Novo Nordisk Inc $125.0004/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899468791 CMS
Novo Nordisk Inc $4,515.0004/05/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899480205 CMS
Abbott Laboratories $129.6503/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920403551 CMS
Mannkind Corporation $35.9603/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756763 CMS
Mannkind Corporation $27.6103/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756765 CMS
Mannkind Corporation $600.0003/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756767 CMS
Mannkind Corporation $2,400.0003/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756769 CMS
Mannkind Corporation $48.3203/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756771 CMS
Novo Nordisk Inc $678.8603/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898719139 CMS
Novo Nordisk Inc $124.9903/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898836059 CMS
Novo Nordisk Inc $3,255.0003/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898898243 CMS
Novo Nordisk Inc $32.2703/02/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898843229 CMS
Amgen Inc. $124.9502/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939405789 CMS
Amgen Inc. $717.0002/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940063177 CMS
Amgen Inc. $2,868.0002/25/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940063179 CMS
Mannkind Corporation $4.6702/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756761 CMS
Esperion Therapeutics, Inc. $125.0002/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258437 CMS
Esperion Therapeutics, Inc. $890.8202/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258425 CMS
Esperion Therapeutics, Inc. $1,079.8202/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258429 CMS
Esperion Therapeutics, Inc. $387.9202/19/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258435 CMS
Esperion Therapeutics, Inc. $4,560.0002/16/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258419 CMS
Novo Nordisk Inc $15.0002/16/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898941875 CMS
Mannkind Corporation $23.0602/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942756759 CMS
Novartis Pharmaceuticals Corporation $18.2402/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893725297 CMS
Novo Nordisk Inc $3.7302/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898941865 CMS
Merck Sharp & Dohme LLC $18.7301/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944504571 CMS
Esperion Therapeutics, Inc. $337.2001/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258383 CMS
Esperion Therapeutics, Inc. $170.2601/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258389 CMS
Esperion Therapeutics, Inc. $36.1201/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258395 CMS
Esperion Therapeutics, Inc. $11.6701/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258399 CMS
Esperion Therapeutics, Inc. $52.9601/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258405 CMS
Esperion Therapeutics, Inc. $20.7801/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258409 CMS
Esperion Therapeutics, Inc. $200.0001/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258415 CMS
Novo Nordisk Inc $4,515.0001/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898589591 CMS
Novo Nordisk Inc $375.9601/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898713623 CMS
Novo Nordisk Inc $119.0501/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898941881 CMS
Novo Nordisk Inc $1,117.9201/27/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899513095 CMS
Esperion Therapeutics, Inc. $6,500.0001/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947258379 CMS
Regeneron Pharmaceuticals, Inc. $68.5801/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927742969 CMS
AstraZeneca Pharmaceuticals LP $112.9701/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915215243 CMS
Novo Nordisk Inc $22.5001/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899360095 CMS
Novo Nordisk Inc $23.7101/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899481871 CMS
Novo Nordisk Inc $2,100.0001/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899044437 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $362,102.25 288
PY2020 $70,592.47 59
PY2021 $156,050.88 157
PY2022 $121,681.21 150
PY2023 $63,137.77 84
PY2024 $104,322.67 100
PY2025 $156,462.00 169

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $127,809.47 32
PY2024 Recipient $1,559.14 10
PY2024 Principal investigator $24,800.92 3
PY2023 Principal investigator $4,656.60 1
PY2022 Principal investigator $22,473.20 4
PY2021 Principal investigator $35,016.94 11
PY2020 Principal investigator $69,456.46 40
PY2019 Recipient $652.48 1
PY2019 Principal investigator $98,630.11 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,889.60 11/25/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,111.66 11/07/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257825
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,714.50 10/31/2025 Non-covered Recipient Entity
YEHUDA HANDELSMAN MD
IS354CS15 No dispute reported 06/30/2026 1246789880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,699.58 10/29/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,284.01 10/23/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252732
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,943.69 10/16/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250823
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,284.01 10/09/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249072
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,400.00 10/08/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA INC
IS354CS9 No dispute reported 06/30/2026 1246788377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,161.36 10/03/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244795
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,284.01 09/23/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241736
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,284.01 09/18/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41,679.51 09/10/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235879
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,284.06 09/03/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $905.00 08/14/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184228393
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,304.79 08/05/2025 Non-covered Recipient Entity
YEHUDA HANDELSMAN MD
IS354CS15 No dispute reported 06/30/2026 1246785988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,923.10 07/22/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,891.70 07/22/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.38 07/22/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,119.40 07/17/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217218
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,819.94 06/19/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,406.60 06/19/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,445.00 06/19/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,819.94 06/12/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206479
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,015.52 05/28/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,015.52 05/22/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,706.24 05/08/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,426.56 04/23/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184188909
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,456.44 04/15/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,064.18 03/19/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174438
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,818.88 02/18/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154356
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,763.64 01/29/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,763.64 01/07/2025 Non-covered Recipient Entity
METABOLIC INSTITUTE OF AMERICA
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145730